Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2009 Aug 29

PMID 19713308

Citations 136

Authors

Kevin E Chan

J Michael Lazarus

Ravi Thadhani

Raymond M Hakim

Affiliations

Soon will be listed here.

Abstract

Use of warfarin, clopidogrel, or aspirin associates with mortality among patients with ESRD, but the risk-benefit ratio may depend on underlying comorbidities. Here, we investigated the association between these medications and new stroke, mortality, and hospitalization in a retrospective cohort analysis of 1671 incident hemodialysis patients with preexisting atrial fibrillation. We followed patient outcomes from the time of initiation of dialysis for an average of 1.6 yr. Compared with nonuse, warfarin use associated with a significantly increased risk for new stroke (hazard ratio 1.93; 95% confidence interval 1.29 to 2.90); clopidogrel or aspirin use did not associate with increased risk for new stroke. Analysis using international normalized ratio (INR) suggested a dose-response relationship between the degree of anticoagulation and new stroke in patients on warfarin (P = 0.02 for trend). Warfarin users who received no INR monitoring in the first 90 d of dialysis had the highest risk for stroke compared with nonusers (hazard ratio 2.79; 95% confidence interval 1.65 to 4.70). Warfarin use did not associate with statistically significant increases in all-cause mortality or hospitalization. In conclusion, warfarin use among patients with both ESRD and atrial fibrillation associates with an increased risk for stroke. The risk is greatest in warfarin users who do not receive in-facility INR monitoring.

Citing Articles

The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management.

Rajesh K, Spring K, Smokovski I, Upmanyue V, Mehndiratta M, Strippoli G Clin Exp Nephrol. 2024; 29(2):149-172.

PMID: 39627467 DOI: 10.1007/s10157-024-02556-w.

Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study.

Dimitrijevic Z, Mitic B, Tasic D, Vrecic T, Paunovic K, Salinger S Medicina (Kaunas). 2024; 60(11).

PMID: 39596945 PMC: 11596554. DOI: 10.3390/medicina60111760.

Anticoagulation in Chronic Kidney Disease.

Montomoli M, Candia B, Barrios A, Bernat E Drugs. 2024; 84(10):1199-1218.

PMID: 39120783 DOI: 10.1007/s40265-024-02077-6.

Direct oral anticoagulants for oral anticoagulants-naïve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis.

Roh J, Kim Y, Kim D, Park S, Park K, Kim M Sci Rep. 2024; 14(1):14679.

PMID: 38918543 PMC: 11199492. DOI: 10.1038/s41598-024-65541-z.

Anticoagulation for Patients With Concomitant Atrial Fibrillation and End-Stage Renal Disease: A Systematic Review and Network Meta-Analysis.

Kao T, Chen Z, Lin Y J Am Heart Assoc. 2024; 13(8):e034176.

PMID: 38606775 PMC: 11262503. DOI: 10.1161/JAHA.123.034176.

References

Gage B, van Walraven C, Pearce L, Hart R, Koudstaal P, Boode B . Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004; 110(16):2287-92. DOI: 10.1161/01.CIR.0000145172.55640.93. View

Connolly S, Laupacis A, Gent M, Roberts R, Cairns J, Joyner C . Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991; 18(2):349-55. DOI: 10.1016/0735-1097(91)90585-w. View

Abbott K, Trespalacios F, Taylor A, Agodoa L . Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003; 4:1. PMC: 149358. DOI: 10.1186/1471-2369-4-1. View

Seliger S, Gillen D, Tirschwell D, Wasse H, Kestenbaum B, Stehman-Breen C . Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol. 2003; 14(10):2623-31. DOI: 10.1097/01.asn.0000088722.56342.a8. View

Keane W, Collins A . Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis. 1994; 24(6):1010-8. DOI: 10.1016/s0272-6386(12)81076-6. View

Lip G, Boos C . Antithrombotic treatment in atrial fibrillation. Postgrad Med J. 2008; 84(991):252-8. DOI: 10.1136/hrt.2005.066944. View

. IV. Patient characteristics at the start of ESRD: data from the HCFA medical evidence form. Am J Kidney Dis. 1999; 34(2 Suppl 1):S63-73. DOI: 10.1053/AJKD034s00063. View

. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995; 333(1):5-10. DOI: 10.1056/NEJM199507063330102. View

Elliott M, Zimmerman D, Holden R . Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007; 50(3):433-40. DOI: 10.1053/j.ajkd.2007.06.017. View

10.

Beyth R, Quinn L, Landefeld C . Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105(2):91-9. DOI: 10.1016/s0002-9343(98)00198-3. View

11.

McClellan W, Soucie J . Facility mortality rates for new end-stage renal disease patients: implications for quality improvement. Am J Kidney Dis. 1994; 24(2):280-9. DOI: 10.1016/s0272-6386(12)80193-4. View

12.

Kopecky S, Gersh B, McGoon M, Chu C, Ilstrup D, Chesebro J . Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med. 1999; 159(10):1118-22. DOI: 10.1001/archinte.159.10.1118. View

13.

Rosamond W, Folsom A, Chambless L, Wang C, McGovern P, Howard G . Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999; 30(4):736-43. DOI: 10.1161/01.str.30.4.736. View

14.

Frost L, Andersen L, Vestergaard P, Husted S, Mortensen L . Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. Neuroepidemiology. 2006; 26(4):212-9. DOI: 10.1159/000092795. View

15.

Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B . Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1(8631):175-9. DOI: 10.1016/s0140-6736(89)91200-2. View

16.

Brophy M, Snyder K, Gaehde S, Ives C, Gagnon D, Fiore L . Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc. 2004; 52(7):1151-6. DOI: 10.1111/j.1532-5415.2004.52314.x. View

17.

Miskulin D, Martin A, Brown R, Fink N, Coresh J, Powe N . Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant. 2004; 19(2):413-20. DOI: 10.1093/ndt/gfg571. View

18.

Lo D, Rabbat C, Clase C . Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. Thromb Res. 2005; 118(3):385-95. DOI: 10.1016/j.thromres.2005.03.031. View

19.

Kokotailo R, Hill M . Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005; 36(8):1776-81. DOI: 10.1161/01.STR.0000174293.17959.a1. View

20.

Jick H, Jick S, Derby L . Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991; 302(6779):766-8. PMC: 1669537. DOI: 10.1136/bmj.302.6779.766. View